Spontaneous, anecdotal, retrospective, open‐label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan)

Abstract Objectives: Our main aim was to investigate the short‐term therapeutic effects, safety/tolerability and potential side effects of the cannabis galenical preparation (Bedrocan) in patients with a range of chronic conditions unresponsive to other treatments. Methods: In this retrospective, ‘compassionate use’, observational, open‐label study, 20 patients (age 18–80 years) who had appealed to our ‘Second Opinion Medical Consulting Network’ (Modena, Italy), were instructed to take sublingually the galenical oil twice a day for 3 months of treatment. The usual starting